Workflow
Aclarion Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
AclarionAclarion(US:ACON) GlobeNewswire News Roomยท2025-03-31 11:00

Core Insights - Aclarion, Inc. has raised over $20 million in Q1 2025, with nearly $15 million in cash on hand, and maintains a clean capital structure with no debt or preferred equity [1][6] - The company is fully compliant with Nasdaq requirements, meeting both bid price and shareholder equity standards [1][6] - The pivotal CLARITY trial for Aclarion's Nociscan is fully funded, with initial interim results expected in Q2 2026 [1][6] Financial and Strategic Highlights - Aclarion has significantly improved its financial positioning and Nasdaq compliance, positioning itself to execute its strategic plan for Nociscan [2] - The company is rapidly enrolling sites for the CLARITY trial, aiming to demonstrate that Nociscan data enhances surgical decision-making and outcomes [2] - Aclarion has secured additional payer approvals in England and expanded physician referral and commercial support for Nociscan in the U.S. [4][6] Product and Market Context - Chronic low back pain (cLBP) affects approximately 266 million people globally, presenting a significant healthcare challenge [4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively help physicians differentiate between painful and nonpainful discs in the lumbar spine [4][5] - The platform utilizes magnetic resonance spectroscopy (MRS) data to quantify chemical biomarkers associated with disc pain, achieving a 97% surgical success rate when treating identified pain-positive discs [4][5]